No headlines found.
Globe Newswire (Sat, 30-May 8:00 AM ET)
Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit
Globe Newswire (Tue, 26-May 4:00 PM ET)
Globe Newswire (Tue, 12-May 4:00 PM ET)
Globe Newswire (Mon, 4-May 1:00 AM ET)
Globe Newswire (Fri, 1-May 7:00 AM ET)
Globe Newswire (Sun, 19-Apr 12:00 PM ET)
Globe Newswire (Tue, 14-Apr 4:00 PM ET)
Globe Newswire (Mon, 23-Mar 9:00 AM ET)
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Molecular Partners Ag - American Depositary Shares trades on the NASDAQ stock market under the symbol MOLN.
As of June 18, 2026, MOLN stock price declined to $3.82 with 1,041 million shares trading.
MOLN has a market cap of $142.86 million. This is considered a Micro Cap stock.
In the last 3 years, MOLN traded as high as $12.70 and as low as $3.32.
MOLN has underperformed the market in the last year with a price return of 0.0% while the SPY ETF gained +26.9%. MOLN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.0% and -2.8%, respectively, while the SPY returned +13.5% and -1.1%, respectively.
MOLN support price is $3.62 and resistance is $4.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MOLN shares will trade within this expected range on the day.